You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 18, 2025

Details for Patent: 9,393,203


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,393,203
Title:Osmotic drug delivery system
Abstract: An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.
Inventor(s): Kidane; Argaw (Montgomery Village, MD), Bhatt; Padmanabh P (Rockville, MD)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:14/881,374
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,393,203
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Delivery; Use;
Patent landscape, scope, and claims:

United States Patent 9,393,203: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

The United States Patent 9,393,203, titled "Osmotic drug delivery system," is a significant innovation in the field of pharmaceuticals, particularly in drug delivery systems. This patent, issued on January 8, 2013, addresses the challenges associated with the release profiles of highly water-soluble drugs.

Background and Context

Osmotic drug delivery systems are designed to release drugs in a controlled manner, often using osmotic pressure to drive the release. These systems are crucial for maintaining therapeutic drug levels over an extended period, which is particularly important for drugs with erratic or incomplete release profiles[1].

Scope of the Patent

The patent 9,393,203 focuses on an oral osmotic pharmaceutical delivery system. Here are the key aspects of its scope:

Drug Characteristics

The system is specifically designed for highly water-soluble drugs that exhibit erratic or incomplete release profiles. This includes drugs like treprostinil, a prostacyclin analog used in the treatment of pulmonary arterial hypertension[1].

Delivery Mechanism

The osmotic delivery system uses osmotic pressure to release the drug. This mechanism ensures a consistent and controlled release of the drug, which is essential for maintaining therapeutic levels and minimizing side effects.

Components and Structure

The system typically includes a solid dosage form with a drug core, an osmotic layer, and sometimes additional components like granular materials, solvents, and sustained-release forms. The osmotic layer is critical as it controls the rate of drug release based on osmotic pressure[1].

Claims of the Patent

The patent includes several claims that define the scope of the invention:

Primary Claims

  • Claim 1 describes the overall osmotic drug delivery system, including the drug core and the osmotic layer.
  • Claims 3-5 specify the composition and structure of the system, including the use of specific materials like treprostinil and the configuration of the osmotic layer[2].

Detailed Composition

  • The claims also detail the use of mixtures, granulation methods, and the role of solvents and sustained-release forms in the delivery system[1].

Patent Landscape

The patent landscape surrounding 9,393,203 is complex and involves several related patents and legal considerations:

Related Patents

  • The patent is part of a series of patents related to the delivery of prostacyclin analogs, including patents like 8,252,839, 8,349,892, and 9,050,311. These patents collectively cover various aspects of drug delivery systems and methods[2].

Legal and Ownership Aspects

  • The patent is owned by UTC (United Therapeutics Corporation), which has exclusive rights to develop, make, use, and sell products covered by this and related patents. This includes the right to sue for infringement[2].

Litigation and Infringement

  • The patent has been involved in legal disputes, with UTC asserting its rights against potential infringers. For example, UTC has filed lawsuits to protect its intellectual property related to the delivery of prostacyclin analogs[2].

Technological and Pharmaceutical Impact

The osmotic drug delivery system described in this patent has significant implications for pharmaceutical technology and patient care:

Controlled Release

  • The system ensures a controlled and sustained release of the drug, which can improve the efficacy and safety of highly water-soluble drugs[1].

Therapeutic Benefits

  • For drugs like treprostinil, this system can provide consistent therapeutic levels, reducing the need for frequent dosing and minimizing side effects.

Future Developments

  • The technology can be adapted for other drugs with similar release profile challenges, expanding its application in various therapeutic areas.

Economic and Market Impact

The economic and market impact of this patent is substantial:

Market Domination

  • By providing a reliable and controlled drug delivery system, UTC can maintain a strong market position in the treatment of conditions like pulmonary arterial hypertension.

Competitive Advantage

  • The exclusive rights granted by this patent give UTC a competitive advantage over other pharmaceutical companies, allowing it to develop and market products without direct competition.

Revenue Generation

  • The controlled release mechanism can lead to higher patient compliance and better therapeutic outcomes, potentially increasing the revenue generated from these products.

Challenges and Limitations

While the patent offers several advantages, there are also challenges and limitations:

Complexity of the System

  • The osmotic delivery system involves complex components and manufacturing processes, which can be challenging to replicate and scale up.

Regulatory Hurdles

  • The system must comply with stringent regulatory requirements, including those related to drug safety, efficacy, and manufacturing standards.

Cost Considerations

  • The development and production of such a system can be costly, which may affect its accessibility and affordability for patients.

Key Takeaways

  • Controlled Drug Release: The patent 9,393,203 describes an osmotic drug delivery system that ensures controlled and sustained release of highly water-soluble drugs.
  • Therapeutic Benefits: This system improves the efficacy and safety of drugs like treprostinil.
  • Market Impact: The patent provides UTC with a competitive advantage and significant market potential.
  • Challenges: The system's complexity, regulatory hurdles, and cost considerations are key challenges.

FAQs

What is the primary focus of the United States Patent 9,393,203?

The primary focus is on an oral osmotic pharmaceutical delivery system designed for highly water-soluble drugs with erratic or incomplete release profiles.

Which drug is specifically mentioned in the patent?

Treprostinil, a prostacyclin analog, is specifically mentioned as an example of a drug that can be delivered using this system.

Who owns the patent?

The patent is owned by United Therapeutics Corporation (UTC).

What are the key components of the osmotic delivery system?

The system includes a drug core, an osmotic layer, and sometimes additional components like granular materials and sustained-release forms.

What are the potential therapeutic benefits of this delivery system?

The system provides consistent therapeutic drug levels, reduces the need for frequent dosing, and minimizes side effects.

Cited Sources

  1. US9393203B2 - Osmotic drug delivery system - Google Patents
  2. IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT ... - Insight.RPXcorp
  3. Patent Claims Research Dataset - USPTO
  4. THE U.S. PATENT APPLICATION PROCESS - SBIR
  5. CosmoKey Solutions GmbH & Co. KG v. Duo Security LLC - CAFC

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,393,203

Showing 1 to 4 of 4 entries

International Family Members for US Patent 9,393,203

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Austria E532520 ⤷  Subscribe
Canada 2649243 ⤷  Subscribe
China 101466384 ⤷  Subscribe
European Patent Office 2010189 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 4 of 4 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.